Abstract: The disclosure pertains to novel eukaryotic cell suitable for recombinant production of a product of interest, wherein the effect of the expression product of an endogenous gene C12orf35 is impaired in said cell, thereby increasing their productivity when recombinantly expressing a polypeptide of interest. Furthermore, the present disclosure provides associated technologies wherein such host cells are used in recombinant production technologies.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
December 21, 2021
Assignee:
Novartis AG
Inventors:
Thomas Jostock, Holger Laux, Anett Ritter
Abstract: The present invention provides a modified eukaryotic cell wherein the modified eukaryotic cell is not able to provide an SSN6-like protein that exerts its wildtype function and/or wildtype activity, the amount of SSN6-like protein being present in the modified eukaryotic cell differs from the amount of SSN6-like protein being present in its wildtype form, and/or essentially no SSN6-like protein is present in the modified cell. Additionally, the present invention provides a polynucleotide sequence comprising a modified ssn6-like gene, and a vector comprising said polynucleoptide. Additionally provided is an expression vector comprising a promoter that is repressed in the presence of SSN6-like protein, and a host cell comprising said vectors. The present invention further refers to a method for determining the purity of a composition by using the modified eukaryotic cell, to a method of expressing gene(s) of interest, and eukaryotic cells comprising modified ssn6-like gene.
Type:
Grant
Filed:
March 2, 2016
Date of Patent:
December 21, 2021
Assignee:
Novartis AG
Inventors:
Clemens Achmüller, Ferdinand Zepeck, Franz Hartner, Thomas Specht
Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Grant
Filed:
July 28, 2020
Date of Patent:
December 21, 2021
Assignee:
NOVARTIS AG
Inventors:
Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
December 21, 2021
Assignee:
NOVARTIS AG
Inventors:
Luigi Franchi, Shomir Ghosh, Gary Glick, Jason Katz, Anthony William Opipari, Jr., William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman, David Guenther Winkler
Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Type:
Application
Filed:
August 24, 2021
Publication date:
December 16, 2021
Applicant:
Novartis AG
Inventors:
BRIAN R. BOETTCHER, SHARI LYNN CAPLAN, DOUGLAS S. DANIELS, NORIO HAMAMATSU, STUART LICHT, STEPHEN CRAIG WELDON
Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
December 7, 2021
Assignee:
Novartis AG
Inventors:
Claire Adcock, Simone Bonazzi, Artiom Cernijenko, Philip Lam, Kathryn Taylor Linkens, Hasnain Ahmed Malik, Noel Marie-France Thomsen, Michael Scott Visser
Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
November 30, 2021
Assignee:
Novartis AG
Inventors:
Rohan Eric John Beckwith, Simone Bonazzi, Artiom Cernijenko, Fupeng Ma, Nathaniel F. Ware
Abstract: The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.
Type:
Grant
Filed:
June 1, 2021
Date of Patent:
November 30, 2021
Assignee:
NOVARTIS AG
Inventors:
Andrew Bryant, Heinrich Buettgen, Wolfgang Papst, Marie Picci
Abstract: The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
November 23, 2021
Assignee:
NOVARTIS AG
Inventors:
Andrew Bryant, Heinrich Buettgen, Wolfgang Papst, Marie Picci
Abstract: The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
Type:
Grant
Filed:
September 16, 2019
Date of Patent:
November 23, 2021
Assignee:
Novartis AG
Inventors:
Daniela Angst, Francois Gessier, Anna Vulpetti
Abstract: The present invention provides compositions comprising a UBC antagonist and methods of use thereof for treating cancer in a patient. In some embodiments, the cancer patient may have a reduced expression level of a UBB gene product. Further provided are reagents and methods for detection of a UBB and/or UBC gene product.
Type:
Grant
Filed:
March 5, 2018
Date of Patent:
November 23, 2021
Assignee:
NOVARTIS AG
Inventors:
William C. Forrester, Alexia T. Kedves-Volpe
Abstract: This invention is in the field of anti-transforming growth factor beta 2 (TGF-?2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-?2 isoform preferentially over the human TGF-?1 or TGF-?3 isoforms.
Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.
Abstract: The invention pertains to an expression vector or a combination of at least two expression vectors comprising at least (a) a polynucleotide encoding a product of interest or an insertion site for incorporating a polynucleotide encoding a product of interest; (b) a polynucleotide encoding a first selectable marker (sm I); (c) a polynucleotide encoding a second selectable marker (sm II), which is different from the first selectable marker (sm I), wherein the activity of the selectable marker (sm I) or (sm II) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm I) and (sm II) are involved in the folate metabolism. Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield.
Abstract: The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
November 9, 2021
Assignee:
NOVARTIS AG
Inventors:
Maximilian Aigner, Alexander Wolfgang Koch, Markus Waldhuber
Abstract: The present application describes an optimized medium for growth of mammalian cells as well as polypeptide production. The cell culture medium is characterized by a Sow ratio of sodium to potassium ions, it further relates to the method of producing polypeptides using such cell culture media. Sn another aspect, the method of polypeptide production can also comprise a temperature shift and/or a pH-shift to further optimize growth and product yield.
Type:
Grant
Filed:
August 28, 2018
Date of Patent:
December 28, 2021
Assignee:
Novartis AG
Inventors:
Christian Leist, Petra Meissner, Jörg Schmidt